Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

ClosetInvetor, The 75 patient trial started last

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155214
(Total Views: 667)
Posted On: 05/05/2020 7:47:01 AM
Avatar
Posted By: TechGuru
Re: ClosetInvestor #32054
ClosetInvetor,
Quote:
The 75 patient trial started last month and has already enrolled 35. The PR this morning said the company expects full enrollment by the end of May. Either that author of this article really didn’t pay attention to the details of the PR, or CYDY is starting another 75 patient phase 2 trial in the U.K. But I find it hard that we’d find out about an approved U.K. trial via a second rate online news organization instead of a PR or from NP.



I believe they are referring to the trial here in USA. They just copied-and-pasted. You are right, it would seem that the trial has been launched locally in the newspaper publication county but I don't think so.

In reference to end of may for full enrollment, I think CYDY should, of course, try and accelerate the enrollment. This trial will finished before the Severe one and will give credibility and public recognition to Leronlimab.

NP said two things in the latest Proactive: there is the possibility that the enrollment is finalized before end of May and the results available end of May. He is being cautious as the speed of enrollment is now in the hands of the trial sites. However, as these augment the rate of enrollment will go up geometrically.

The second point he made is that at the end of P2 Mild-to-Moderate FDA will have proof of safety and efficacy and mentioned: "this is what the FDA needs for approval".

So, we don't know when the recruitment will be completed, obviously we all hope sooner that later. What it is CRITICAL are the results.

If we blow the p-number out of the water FDA will be under extreme pressure to bring Leronlimab to the market swiftly, and I mean EXTREME pressure.

One thing is to sing the praises in the oval office of a drug that helps to somewhat reduce the hospital stay if administered early (only) in a fudged, "open" trial and another to try and hide a drug that in a double-blinded trial demonstrated irreputable therapeutically benefit.

I say lets' get a 0.001 p-number !!!! Go CYDY !!!!

The prize will be huge !!!!!! Lives saved in the 100's of thousands (no exaggeration here)




(6)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us